The colour test for drug susceptibility testing of Mycobacterium tuberculosis strains

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 8, 2012, Pages 1113-1118

  Toit, Kadri ^a   Mitchell, S ^b   Balabanova, Y ^b   Evans, C A ^c,d   Kummik, T ^a   Nikolayevskyy, V ^b   Drobniewski, F ^b  

^a TARTU UNIVERSITY HOSPITAL   (Estonia)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

Estonia; Fluoroquinolones; Multidrug resistant tuberculosis; Thin layer agar

Indexed keywords

CIPROFLOXACIN; ISONIAZID; RIFAMPICIN;

AGAR MEDIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; COLOR VISION TEST; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC KIT; FEASIBILITY STUDY; GOLD STANDARD; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REACTION TIME; SENSITIVITY AND SPECIFICITY; THIN LAYER AGAR;

ANTITUBERCULAR AGENTS; CIPROFLOXACIN; COLOR; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESTONIA; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEASIBILITY STUDIES; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84862202170     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0609     Document Type: Article

References (34)

1. World Health Organization. The Global Plan to Stop TB, 2011-2015. WHO/HTM/STB/2010.2. Geneva, Switzerland: WHO, 2010.
2. Raviglione M. XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis 2006; 10: 1185-1187. (Pubitemid 44713471)
3. Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin-layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 688-698.
4. Morcillo N, Imperiale B, Di Giulio B. Evaluation of MGIT 960™ and the colorimetric-based method for tuberculosis drug susceptibility testing. Int J Tuberc Lung Dis 2010; 14: 1169-1175.
5. Marttila H J, Marjamäki M, Viljanen M K, Soini H. Performance of BACTEC 960 Mycobacteria Growth Indicator Tube in the susceptibility testing of genetically characterized Mycobacterium tuberculosis isolates. Eur J Clin Microbiol Infect Dis 2003; 22: 757-759. (Pubitemid 38019319)
6. Bemer P, Palicova F, Rüsch-Gerdes S, Drugeon H B, Pfyffer G E. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 150-154. (Pubitemid 34027617)
7. Krüüner A, Yates M D, Drobniewski F A. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 811-818.
8. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis 2008; 12: 1449-1455.
9. Rüsch-Gerdes S, Pfyffer G E, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-692.
10. Balabanova Y, Drobniewski F, Nikolayevskyy V, et al. An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia. PLoS One 2009; 4: e7129.
11. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-2640. (Pubitemid 47295497)
12. Causse M, Ruiz P, Gutierrez J B, Zerolo J, Casal M. Evaluation of new GenoType® MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008; 12: 1456-1460.
13. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacincapreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-1772.
14. Boehme C C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
15. Hillemann D, Rüsch-Gerdes S, Boehme C, Richter E. Molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF System. J Clin Microbiol 2011; 49: 1202-1205.
16. Welch D F, Guruswamy A P, Sides S J, Shaw C H, Gilchrist M J R. Timely culture for mycobacteria which utilizes a microcolony method. J Clin Microbiol 1993; 31: 2178-2184. (Pubitemid 23210515)
17. Mejia G I, Castrillon L, Trujillo H, Robledo J A. Microcolony detection in 7H11 thin layer culture is an alternative for rapid diagnosis of Mycobacterium tuberculosis infection. Int J Tuberc Lung Dis 1999; 3: 138-142. (Pubitemid 29151817)
18. Runyon E H. Identification of mycobacterial pathogens utilizing colony characteristics. Am J Clin Pathol 1970; 54: 578-586.
19. Robledo J A, Mejía G I, Morcillo N, et al. Evaluation of a rapid culture method for tuberculosis diagnosis: a Latin American multi-center study. Int J Tuberc Lung Dis 2006; 10: 613-619. (Pubitemid 43845021)
20. Martin A, Fissette K, Varaine F, Portaels F, Palomino J C. Thinlayer agar compared to BACTEC MGIT 960 for early detection of Mycobacterium tuberculosis. J Microbiol Methods 2009; 78(1): 107-108.
21. Satti L, Ikram A, Abbasi S, Malik N, Mirza I A, Martin A. Evaluation of thin-layer agar 7H11 for the isolation of Mycobacterium tuberculosis complex. Int J Tuberc Lung Dis 2010; 14: 1354-1356.
22. Schaberg T, Reichert B, Schülin T, Lode H, Mauch H. Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media. Eur Respir J 1995; 8: 1688-1693.
23. Robledo J, Mejia G I, Paniagua L, Martin A, Guzmán A. Rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis by the direct thin-layer agar method. Int J Tuberc Lung Dis 2008; 12: 1482-1484.
24. Herrera B, Gilman R H, Grandjean L, et al. Optimisation of TB field testing: in transit sputum decontamination & culture on colorimetric selective media for TB diagnosis & drug-susceptibility testing. Symposium on TB Field Diagnostics: 'Dying for a Test'. Cape Town, South Africa: Médecins Sans Frontières (MSF) Campaign for Access to Essential Medicines, 7 November 2007: pp 15-16. http://www.msfaccess.org/sites/default/ files/MSF-assets/TB/Docs/TB-event-DyingforaTest-ENG-2007.pdf Accessed May 2012.
25. Von Groll A, Martin A, Jureen P, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009; 53: 4498-4500.
26. Devasia R A, Blackman A, May C, et al. Fluoroquinolone r esistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother 2009; 63: 1173-1178.
27. Lee S M, Kim J, Jeong J, et al. Evaluation of the broth microdilution method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing. J Korean Med Sci 2007; 22: 784-790.
28. Lee S, Kong D H, Yun S H, et al. Evaluation of a modified a ntimycobacterial susceptibility test using Middlebrook 7H10 agar containing 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride. J Microbiol Methods 2006; 66: 548-551. (Pubitemid 44062003)
29. Herrera B, Ramos E, Gilman R, et al. A simple colour test for diagnosing MDR-TB and XDR-TB under field conditions. 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France, October 2008. [Poster presentation at CDC late-breaker session on TB]. http://ifhad.org/Abstracts/2008/IUATLD%20Paris%20Abst/ Herrera%20B%202008%20px%20%20Simple%20colour%20test%20MDRTB%20& %20XRTB%20late%20breaker%20Paris%20CAWE%20zx.pdf Accessed June 2012.
30. Ellis R C, Zabrowarny L A. Safer staining method for acid-fast bacilli. J Clin Pathol 1993; 46: 559-560. (Pubitemid 23209857)
31. Siddiqi S, Rüsch-Gerdes S, Alexander H, Drobniewski F, Feldman K. MGIT procedure manual. For BACTEC™ MGIT 960™TB System (also applicable for Manual MGIT) Mycobacteria Growth Indicator Tube (MGIT) culture and drug susceptibility demonstration projects. Geneva, Switzerland: FIND, 2006. www.finddiagnostics.org/resource-centre/reports-brochures/071130-mgit-manual. html Accessed May 2012.
32. World Health Organization. Policy guidance on drugs usceptibility testing (DST) of second-line anti-tuberculosis drugs. WHO/HTM/TB/2008.392. Geneva, Switzerland: WHO, 2008.
33. Martin A, Paasch F, Von Groll A, et al. Thin-layer agar for detection of resistance to rifampicin, ofloxacin and kanamycin in Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2009; 13: 1301-1304.
34. Kim S J, Lee S H, Kim I S, Kim H J, Kim S K, Rieder H L. Risk of occupational tuberculosis in National Tuberculosis Programme laboratories in Korea. Int J Tuberc Lung Dis 2007; 11: 138-142. (Pubitemid 46219275)